Kanada - Inggeris - Health Canada

taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 12.5mg - sunitinib (sunitinib malate) 12.5mg

Kanada - Inggeris - Health Canada

taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 25mg - sunitinib (sunitinib malate) 25mg

Kanada - Inggeris - Health Canada

taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 50mg - sunitinib (sunitinib malate) 50mg

Kanada - Inggeris - Health Canada

auro pharma inc - sunitinib (sunitinib malate) - capsule - 12.5mg - sunitinib (sunitinib malate) 12.5mg

Kanada - Inggeris - Health Canada

auro pharma inc - sunitinib (sunitinib malate) - capsule - 25mg - sunitinib (sunitinib malate) 25mg

Kanada - Inggeris - Health Canada

auro pharma inc - sunitinib (sunitinib malate) - capsule - 37.5mg - sunitinib (sunitinib malate) 37.5mg

Kanada - Inggeris - Health Canada

auro pharma inc - sunitinib (sunitinib malate) - capsule - 50mg - sunitinib (sunitinib malate) 50mg

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sunitinib malate, quantity: 66.825 mg (equivalent: sunitinib, qty mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide black; iron oxide yellow; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - arx-sunitinib is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sunitinib malate, quantity: 50.119 mg (equivalent: sunitinib, qty mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - arx-sunitinib is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sunitinib malate, quantity: 33.413 mg (equivalent: sunitinib, qty 25 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; iron oxide red; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - arx-sunitinib is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).